Mycobacterium paratuberculosis (MPT) is the etiologic agent of paratuberculosis. The disease is prevalent in cattle worldwide, and exacts a heavy financial toll. Effective control requires the development of acellular vaccines offering a better protection than the current available vaccines without side effects and allowing the discrimination between infected and vaccinated animals. We studied the immune response of mice to the MPT superoxide dismutase (SOD) alone or adjuvanted by Ribi. We cloned, overexpressed and purified this antigen in Escherichia coli. Spleen cells from immunized mice, after exposure to recombinant MPT SOD (MPT rSOD), produced significant levels of IFNQ, TNFK and IL-6. IFNQ and TNFK production was increased by the addition of Ribi. In contrast, low levels of NO, IL-4 and IL-10 were secreted by spleen cells culture from immunized mice. The immunoglobulin isotype distribution analysis showed that Ribi adjuvant clearly induced a significantly higher anti-MPT rSOD antibody production of all classes tested and decreased the IgG1/ IgG2a ratio thus improving the Th1 response. Delayed-type hypersensitivity responses in mice footpads were observed only in mice immunized with MPT rSOD emulsified in Ribi. Vaccination of MPT rSOD emulsified with Ribi induced both a Th2 and Th1 type of immune response with the later slightly more pronounced. The results presented here on the immunogenicity of MPT SOD suggest that this antigen should be further tested as a candidate antigen for a future acellular vaccine against paratuberculosis. ß
Introduction
Mycobacterium paratuberculosis (MPT) is the etiological agent of gastroenteritis, known as paratuberculosis or Johne's disease [1^3] . Paratuberculosis is a chronic debilitating disease of cattle and other ruminants characterized by profuse diarrhea, dehydration and death. Mastitis, infertility, prolonged intercalving intervals, decreased milk production are additional clinical manifestations of Johne's disease [1] . Cattle usually become infected with MPT as calves by contact with feces or milk contaminated with the bacteria. After invasion via the surface of the gastrointestinal tract, the bacteria are phagocytosed by macrophages in which they continue to grow and multiply slowly. In£ammation and granulomatous lesions occur in the ileum and the colon while MPT is shaded into the feces in large numbers perpetuating the cycle of infection. The disease is prevalent worldwide, and exacts a heavy ¢nancial toll. In the United States of America, the high prevalence of paratuberculosis in dairy cattle [4, 5] results in 14% and 18% of the culling of cows in most a¡ected areas. Estimated losses to the agriculture industry are in excess of $1.5 billion annually [2] . A mathematical model of paratuberculosis based on the percentage of culled cows with clinical signs of the disease estimates that the losses to the agricultural industry are in the range of $40 to $227 per cow inventoried per year [6] .
The strategy for control and eradication of the disease includes surveillance of herds for the presence of infected cattle, followed by culling and changes in herd manage-ment [3, 7] . Paratuberculosis vaccines are available but are not very e¡ective in preventing the disease [3] . These vaccines are based on live attenuated vaccine such as strain 316F, or heat-killed bacteria [3] . These vaccines produce granulomas at the site of injection and animals with antibodies/delayed-type hypersensitivity (DTH) reaction that cannot be di¡erentiated from those of naturally infected animals. A live attenuated vaccine compatible with diagnostics has not yet been developed. Thus, at this stage, especially for situations where culling is not economically feasible, an e¡ective control requires the development of acellular vaccines o¡ering a better protection than the current available vaccines without side e¡ects. These improved vaccines should be readily compatible with the current diagnostic tests and should allow the discrimination between vaccinated and infected animals. Such vaccines can only be developed with a more thorough understanding of MPT antigenic determinants.
Proteins secreted by mycobacteria are of special interest. These proteins are likely to be involved in mediating the interaction between the pathogens and host cells during the infection. In addition to being involved in pathogenesis and virulence, secreted proteins are also likely to become available for immune recognition in early stages following infection and may therefore have an important role in the protective response against these pathogens. Superoxide dismutase (SOD) is found within the bacteria but extracellular SOD has been also observed in Mycobacterium tuberculosis (MTB) [8] . Indeed, Andersen et al. [9] found the SOD to be among the three main secreted protein of MTB. Like the MTB SOD, the SOD of Mycobacterium avium was shown to be secreted without a peptide leader [10, 11] . The presence of SOD and seven other enzymes in MTB and Mycobacterium bovis culture ¢l-trates and their absence in those of non-pathogenic mycobacteria indicated that secretion of SOD may be correlated with mycobacterial virulence [12] . MPT was shown to produces ¢ve-fold less SOD than MTB, but 20-fold more than the non-pathogenic Mycobacterium smegmatis [10, 13] . Recently it has been suggested that the high extracellular levels of SOD in actively growing culture is not due to active secretion but to leakage or bacterial autolysis [14] . Detection of SOD in the extracellular medium is due to the high level of expression and the high stability of this protein [14] . Anti-SOD antibodies are found in tuberculosis and leprosy patients [8] . Furthermore, Mycobacterium habana (Mycobacterium simiae serovar 1) SOD was recognized by T cells from guinea pigs, mice and Mycobacterium leprae infected human [15] . All these data indicate the possible roll of MPT SOD as a potential protective antigen for a MPT vaccine. The aim of this work was to assess the immune response of mice towards MPT SOD in order to evaluate if this antigen can be a component of a future acellular vaccine against paratuberculosis.
Materials and methods

Cloning, expression and puri¢cation of MPT SOD in Escherichia coli
Primers derived from the sequence of MPT sodA gene [13] containing BglII and NcoI sites for subcloning into pQE60 (Qiagen, Diagen, Germany) were synthesized at the Hebrew University central facilities. DNA of pBUN154 [13] containing the MPT SOD gene (GenBank accession number AF180816) was used as a template for PCR ampli¢cation. The primers used were 5P-GCGCC-CATGGCTGAATACACCCTG-3P and 5P-GGAAGATC-TGCCGAAGATCAGGCC-3P. Standard PCR conditions were used (Vent DNA polymerase, New England Biolabs, USA) ; 36 cycles of ampli¢cation (94 ‡C for 1 min, 50 ‡C for 1 min and 72 ‡C for 1.5 min). The ampli¢ed DNA fragment was puri¢ed by agarose gel separation followed by gene clean extraction (Geneclean II kit, BIO 101, USA) and then digested with both NcoI and BglII. The puri¢ed MPT sodA DNA was ligated to the E. coli pQE60 plasmid expression vector predigested by NcoI and BglII. The plasmid pQE60 encodes six histidines that are tagged to the COOH terminus of the expressed protein. These histidines enabled easy puri¢cation of the recombinant protein by a⁄nity chromatography with immobilized nickel chelate [nickel^nitrilotriacetic acid (Ni^NTA) column]. After ligation (2 h at 20 ‡C with 2 U of T4 ligase, IBI, USA), the resulting plasmid pHB23 containing the MPT sodA sequence was used to transform E. coli SG13009 strain. Overexpression and puri¢cation of recombinant MPT SOD (MPT rSOD) was done as previously described [16] .
N-terminal amino acid sequence determination of the MPT SOD protein
The MPT rSOD protein was separated by SDS^PAGE, sodium dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^PAGE) and electroblotted onto polyvinylidene £uo-ride membrane (Gelman Sciences, USA). The protein was identi¢ed by Coomassie blue staining and was N-terminal sequenced with a Perkin Elmer micro sequencer system 492 (Applied Biosystems Division).
Immunization protocol and spleen cells culture
Speci¢c pathogen-free (SPF) female BALB/c mice, 5^8 weeks old, were injected subcutaneous (s.c.) with 50 Wg of MPT rSOD or MPT rSOD emulsi¢ed in Ribi adjuvant composed of synthetic trehalose dicorynomycolate (TDM) and monophosphoryl lipid A (MPL). (MPL/TDM Ribi, Sigma Chemical Co., USA). Two weeks after the ¢rst injection, mice were re-immunized the same way. Two weeks later, the animals were killed and spleen cells were harvested for cytokine, nitric oxide (NO) determination and proliferation assay. Spleen cells were grown in 96-well plate (Nunc, Denmark) in a concentration of 700 000 cells/220 Wl for cytokine/NO determination and 250 000 cells/200 Wl for the proliferation assay. RPMI medium (Biological Industries, Israel) supplemented with 10% fetal calf serum (FCS, Biological Industries, Israel), 1 mM glutamine (Biological Industries, Israel), 25 mM HEPES (Biological Industries, Israel), 5U10
35 M 2-mercaptoethanol (Merck, Germany), (100 U ml 31 ) penicillin, (100 Wg ml 31 ) streptomycin and (12.5 U ml 31 ) nystatin (Biological Industries, Israel) were used for in vitro cultures. In a preliminary study, cells were stimulated with three di¡erent protein concentrations (5, 20 and 50 Wg protein ml 31 ) or with ConA. Cytokines and NO production from spleen cells were monitored. The optimal concentration for the MPT rSOD was 20 Wg ml 31 protein for cytokines, NO and proliferation assays. Positive controls included spleen cells from naive mice stimulated with ConA (5 Wg ml 31 ). Negative controls included spleen cells from naive mice stimulated with MPT rSOD in vitro and spleen cells from mice vaccinated with Ribi and stimulated with MPT rSOD in vitro. The baseline values of the cytokines and NO productions (data not shown) did not di¡er statistically at the various concentrations of the recombinant protein indicating that LPS contamination, if existing, was minor.
Cytokine assays
Secretion of IL-10, IL-6, IL-4 and IFNQ was monitored in supernatant of spleen cells collected at di¡erent intervals during in vitro cultures. Cytokines' levels were determined by enzyme-linked immunosorbent assay (ELISA) as previously described [16] , using commercial pairs of antibodies and recombinant cytokines (Pharmingen International, USA), according to the manufacturer's instructions. TNFK levels were assessed by an ELISA kit (Biosource International, USA) according to the manufacturer's instructions. The range of the sensitivities of the ELISA for the relevant murine cytokines was 150^5000 pg ml 31 for IFNQ and 15^2000 pg ml 31 for IL-4, TNFK, IL-6 and IL-10.
NO determination
NO levels were measured by the Griess assay [17] . Brie£y, 100 Wl of the supernatant of the spleen cells cultures were transferred to 96-well plates and 100 Wl of Griess reagent (Sigma Chemical Co., USA) was added. After incubation at room temperature, absorption was read at a wavelength of 550 nm using an ELISA reader (ELX-800UV, Bio-Tec Instruments, USA). Units of NO were determined by comparison with a standard curve using sodium nitrate (Sigma Chemical Co., USA). The range of the sensitivity of this test was 0.1^6 Wmol ml 31 NO.
Proliferation assay
After 96 h of incubation with MPT rSOD, spleen cells were pulsed with 0. 
Serum antibody titers
Antibody titers against MPT rSOD (IgG1, IgG2a, and total IgG) were assessed by ELISA as previously described [16] . We used anti mouse IgG alkaline phosphatase conjugate (Sigma Chemical Co., USA), anti mouse IgG1 alkaline phosphatase conjugate (Southern Biotechnology, USA) and anti mouse IgG2a alkaline phosphatase conjugate (Southern Biotechnology, USA). Absorption was read at a wavelength of 405 nm using an ELISA reader (ELX-800UV, Bio-Tec Instruments, USA). Serum titers were calculated from a regression line generated by values taken at three sequential dilution points. 0.1 OD above blank samples was considered as a positive result. This value (0.1 OD) was more than three times higher than the average OD reading of the blank samples plus three standard deviations.
DTH studies
The DTH in mice was assayed in three groups of seven mice each: MPT rSOD-immunized mice, MPT rSOD+Ri-bi-immunized mice and Ribi-immunized mice. DTH measurement was performed 24 h after injection into the footpads of 10 Wg of MPT rSOD in 20 Wl of PBS. The swelling was measured in the footpad with a calliper (Mitutoyo, Japan) with a minimum measurable increment of 0.01 mm. Footpad swelling was expressed as the di¡erence between the swelling observed in MPT rSOD injected footpad and the swelling observed in PBS injected footpad.
Ethical considerations and animal maintenance
All experiments were performed in accordance with the regulations of the animal experimentation ethics committee of Hadassah Medical School, Hebrew University. SPF female BALB/c mice were maintained in SPF conditions and used at 6^8 weeks of age (16^18g).
Statistics and sequence analysis
All DNA and protein sequences were analyzed by MacVector 7.0 program (Oxford Molecular, UK). Proliferation, NO, cytokines and serum antibody determinations were done on pooled samples of eight to 10 mice. The immunization experiments were repeated three to six times. Data were analyzed by Student's t-test, and di¡er-ences with P 6 0.05 were considered signi¢cant. The results shown are the mean. 
Expression, puri¢cation and N-terminal amino acid sequence of MPT rSOD protein in E. coli
The plasmid pHB23 was used to transform E. coli SG13009 strain. The six histidines tagged at the COOH terminus of the recombinant protein enabled puri¢cation of the product with the Ni^NTA column (Fig. 1) . The recombinant protein was overexpressed in E. coli at a level of 4 mg per liter of culture. SDS^PAGE analysis revealed the presence of one protein band with a molecular mass of 28 kDa (Fig. 1) . The theoretical molecular mass of the MPT rSOD protein with or without the six histidines tagged at the end should be 24 kDa and 23 kDa respectively. N-terminal amino acids sequence of the 28-kDa overexpressed protein (AEYTLPDLDWDYAAL) exactly matched the amino acid sequence predicted from the nucleotide sequence upon post-translational elimination of the N-terminal methionine.
Cytokines and NO secretion by spleen cells
Cytokines and NO levels were evaluated in the supernatants of the cultures of spleen cells exposed to 20 Wg protein ml 31 of MPT rSOD, using a sandwich ELISA and the Griess assay. Signi¢cantly higher amounts of IFNQ, TNFK and IL-6 (P 6 0.005 throughout most of the kinetic time) were released from spleen cells of immunized mice compared to non-immunized mice spleen cells or Ribi-immunized mice spleen cells ( Fig. 2A,C,F ). In contrast, IL-10, IL-4 and NO were produced in relatively low amounts by spleen cells from immunized mice with or without Ribi (Fig. 2B,D,E) . The addition of Ribi to the rSOD resulted in a signi¢cantly higher amount of IFNQ released by spleen cells from the immunized mice (maximum of 2530 pg ml 31 ) compared to spleen cells from MPT rSOD-immunized mice (maximum of 1820 pg ml 31 ). IL-6 production was similar in immunized mice with or without Ribi (Fig. 2C) .
Spleen cell proliferation response
The average cpm obtained from spleen cells of mice immunized with MPT rSOD in Ribi after exposure in vitro to MPT rSOD was 17787 whereas the average cpm obtained from spleen cells from mice immunized with Ribi alone with no exposure in vitro to the antigen was 4321. Spleen cells from mice immunized with MPT rSOD+Ribi demonstrated a SI signi¢cantly higher (P 6 0.005) than that of spleen cells from mice immunized with MPT rSOD only (SI = 3.1 þ 0.35 and SI = 1.9 þ 0.21 respectively). Yet both immunization regimens showed SI greater (P 6 0.005) than that of spleen cells of mice immunized with Ribi alone and exposed to MPT rSOD (SI = 1.2 þ 0.18), but lower than that of the naive control group exposed to ConA (SI = 7.6 þ 0.98).
Speci¢c IgG subclass ratio determination
To evaluate the humoral response of mice, speci¢c antibodies were determined by ELISA. Speci¢c antibodies were detected in all the sera of the immunized mice (OD s 0.1) in a dilution range of 1:200^1 :2000, whereas no speci¢c anti-MPT rSOD antibodies of any class were found in the naive control group. Fig. 3 shows the relative levels of speci¢c anti-MPT rSOD antibodies in the sera of immunized mice. A 14.7 higher fold of speci¢c anti-MPT rSOD IgG2a antibodies level was observed upon immunization of mice with MPT rSOD emulsi¢ed in Ribi as compared to the level obtained when mice were immunized with MPT rSOD alone. Ribi adjuvant also enhanced, the production of speci¢c anti-MPT rSOD IgG1 (7.7-fold) and total anti-MPT rSOD IgG (7.4-fold). As a result, the IgG1/IgG2a ratio in mice immunized with MPT rSOD alone was 12 and the IgG1/IgG2a ratio in mice immunized with MPT rSOD with Ribi was 1.8.
DTH studies
Swelling of the footpads was observed only in mice immunized with MPT rSOD emulsi¢ed in Ribi (mean swelling of 0.21 þ 0.03 mm) whereas mice immunized with MPT rSOD alone or with Ribi showed no signi¢cant swelling when compared to the injection of PBS in the contra-lateral footpad.
Discussion
The molecular mass of the native MPT SOD is 23 kDa [13] . The MPT rSOD that we puri¢ed on Ni^NTA column had a molecular mass of 28 kDa in SDS^PAGE. The ConA, (R) spleen cells of naive mice exposed in vitro to MPT rSOD, (S) spleen cells of mice immunized with Ribi alone and exposed in vitro to MPT rSOD. The results shown are the mean and S.D. of three to six experiments with eight to 10 mice in each group. Data were analyzed by Student's t-test. *P 6 0.025 and **P 6 0.005 when data were compared with the value of spleen cells of naive or Ribi-immunized mice exposed in vitro to MPT rSOD. di¡erence in migration between the MPT rSOD and the native SOD probably results from the presence of six histidines in the recombinant protein. Such a change in electrophoretic characteristics was previously observed [16, 18] . However, the N-terminal amino acid sequences con¢rmed that the protein expressed was the MPT SOD.
Since MPT multiplies mainly inside mononuclear phagocytes in the primary stage of infection, it is assumed that the resulting pathology is controlled by the cellular immune response [19] . Extracellular antigens of mycobacteria such as the MPT SOD can play a key role in the recognition by the host of the invading pathogen and may induce a protective response against intracellular pathogen such as MPT. Indeed serological studies showed the presence of antibodies to SOD in all the tuberculosis patients tested and in 84% leprosy patients [8] . In addition, MTB SOD and M. habana (M. simiae serovar 1) SOD were able to elicit a DTH reaction in immunized guinea pigs [8, 20] .
There is no published data de¢ning mycobacterial manganese-dependent SOD epitopes that are recognized by the immune system of animals or man. Therefore we computer-analyzed thoroughly the amino acid sequences of mycobacterial SODs. Protein sequence analysis revealed that the MPT SOD has 89% similarity to the M. leprae SOD (accession number s06599), 81% similarity to MTB SOD (accession number s15205) and 93% similarity to M. habana SOD (accession number x81390). Potential epitope peptides were deduced by computer analysis based on predicted half time of dissociation to MHC class I molecules [20] . Two 8-mer peptides that contain binding motifs for MHC class I (H-2Kd) molecules in mice were identi¢ed, IFLNEKNL starting at position 59 and FYL-QYKNV starting at position 166. The MPT SOD peptide starting at position 166 showed 100% identity to the homologous epitopes of MTB, M. leprae and M. simiae SODs. The MPT SOD peptide starting at position 59 showed 100% identity to the homologous epitopes of M. leprae and M. simiae SOD (accession number x81390). Two other MPT SOD 10-mer peptides containing a binding motif for MHC class I (H-2Kd) molecules in mice were identi¢ed: LYDQQANVPL starting at position 142 and DYVKAFWNVV starting at position 176. Both peptides showed 100% identity to the homologous epitopes of SOD from M. simiae and the later peptide showed 100% identity to the homologous epitopes of M. leprae SOD. The MPT SOD 10-mer peptide TYVKGVNDAL starting at position 35 showed a binding motif for MHC class I (H-2Kd) molecule in mice. Comparison of this MPT SOD amino acid sequence to MTB, M. leprae and M. simiae SOD sequences revealed that this region is unique to MPT. Analysis of MPT SOD peptides for domains containing binding motifs for MHC class I (A20) molecules in cows revealed two peptides : VKGVNDALAK starting at position 37 and YKNVKADYVK starting at position 170. Both peptides showed 100% identity to the homologous epitopes of SOD from M. leprae and the later peptide showed, in addition, 100% identity to the homologous epitopes of M. simiae SOD. The homologies found among the computer-deduced epitopes can forecast cross-reactions between SODs of di¡erent mycobacteria but also indicate the quality of the SOD as a potential protective antigen not only in mice but also in cow. This is also strengthened by the analysis of cytokines induced by immunization of mice with SOD.
IFNQ is generally regarded as the major component in activation of macrophages and is produced by memory immune cells in e¡ective MTB vaccination experiments [21, 22] . In the present study we showed that spleen cells from MPT rSOD-immunized mice produced a signi¢cant amount of IFNQ and IL-6 that could indicate a potential protection against MPT. However, recent studies showed that IFNQ activated macrophages [23] are not always able to eliminate M. avium. This observation suggests that there are additional T-cell signals required for the eradication of mycobacteria within macrophages. The additional presence of IL-6 can play an important role in the induction of protective immunity against M. avium [24, 25] . Moreover, TNFK is required for the initial control of mycobacterial infection due to its extensive range of pro-in£ammatory and macrophage-activating function [26] . Our observation that spleen cells from vaccinated mice produce TNFK may further indicate that vaccination with MPT SOD could induce a protective response against MPT. The lack of IL-10, IL-4 and low NO production after SOD immunization, even when emulsi¢ed in Ribi, endorses the hypothesis that MPT SOD favors a Th1 response.
An optimal adjuvant for vaccination must induce a protective immune response with di¡erent antigens and without side e¡ects. Since no adjuvant known has all the above qualities, each new antigen evaluation requires the study of an appropriate adjuvant as well. The results presented here show that Ribi favored a Th1 response by inducing both a higher IFNQ production and higher levels of anti MPT rSOD IgG2a antibodies, resulting in a shift of the IgG1/IgG2a ratio (IgG1/IgG2a ratio of 1.8 versus 12 without Ribi). Production of IgG2a can magnify the complement classic pathway while IgG1 inhibit complement activity [27] . Thus immunization with MPT rSOD emulsi¢ed in Ribi can in theory, promotes the lysis of MPT when the bacteria are extracellular via the complement system and induces a cellular immune response able to clear intracellular bacteria.
DTH response requires coordination and strict balance of immune cells such as CD4 T cells and immune signals such as IFNQ. CD4 T cell response is necessary for protective against intracellular pathogen such as MTB [28, 29] . DTH is a good indicator of CD4 T cell sensitization. Our ¢ndings that only mice immunized with MPT rSOD with Ribi showed a DTH reaction further demonstrates that the Ribi adjuvant contributes to the Th1 immune response.
MPT has developed mechanism to survive cell-mediated immune response. A better understanding of these mechanisms and the search for other MPT potentially protective antigens are necessary for the development of an e⁄-cient vaccination. In conclusion, the abundance of SOD in mycobacteria and the immunological properties of MPT rSOD suggest that this antigen can be a potential candidate for a future acellular vaccine against paratuberculosis.
